Rectal Cancer: Major Surgery Avoided by 80% in Trial
A breakthrough trial shows 80% of early-stage rectal cancer patients can avoid surgery after chemoradiotherapy, potentially transforming treatment and preserving organs.
The Cliff News | 28 August 2026
A groundbreaking clinical trial has revealed that a significant majority of patients diagnosed with early-stage rectal cancer can now potentially avoid invasive major surgery. The findings, from the STAR-TREC trial, indicate that 80% of participants were able to retain their rectum intact after undergoing a combination of chemotherapy and radiotherapy.
This revolutionary approach, if widely adopted, could fundamentally alter the standard of care for many individuals facing this diagnosis, reserving surgical intervention for only those cases where it is absolutely essential.
New Treatment Pathway Emerges
The STAR-TREC trial, a collaborative effort funded by esteemed organizations such as Cancer Research UK and Stand Up To Cancer, involved researchers from leading institutions including University College London, the University of Birmingham, and the University of Leeds.
Their pioneering method involves a two-pronged strategy. Patients first receive chemoradiotherapy, a powerful treatment that combines chemotherapy drugs with radiation therapy. The primary goal of this initial phase is to significantly shrink the size of the cancerous tumour or, in some cases, eliminate it entirely.
Close Monitoring Replaces Surgery
Following the chemoradiotherapy, the trial participants undergo a period of intensive and close monitoring. This crucial stage allows medical professionals to meticulously assess the tumour's response to the treatment. Doctors closely observe whether the cancer has disappeared or responded satisfactorily to the therapy.
If the cancer shows significant regression or is no longer detectable, patients can then successfully bypass the need for extensive surgical procedures. This organ-preserving outcome marks a significant advancement in patient care and quality of life.
Conversely, the trial protocol ensures that patients whose cancer does not respond adequately to chemoradiotherapy are still identified. These individuals will then proceed to undergo surgery, ensuring that all necessary treatment pathways are addressed to combat the disease effectively. The STAR-TREC approach thus offers a more tailored and less invasive treatment journey for a large proportion of patients.